Cannabinoid receptor type 1 (CB1R) antagonists/inverse agonists have the potential for treating obesity [2], obesity-related cardiometabolic disorders [3], and drug/substance abuse [4]; however, there is no such drug currently available on the market. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.